Compounds > astragaloside a
Page last updated: 2024-09-03

astragaloside a and Parkinson Disease

astragaloside a has been researched along with Parkinson Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's2 (40.00)2.80

Authors

AuthorsStudies
Chen, IY; Kuo, YC; Rajesh, R1
Ge, B; Li, FR; Li, SL1
Alves, RD; Cavalcante, JS; Cavalcanti, JRLP; Costa, IM; Fernandes, LCB; Filho, IA; Freire, MAM; Guzen, FP; Lima, FOV; Lucena, EES; Neta, FI; Norrara, B; Queiroz, DB; Rego, ACM1
Chan, WS; Durairajan, SS; Koo, I; Kum, WF; Li, M; Lu, JH; Wang, Y; Xie, LX; Yung, KK1
Gao, GD; Li, LH; Qin, HZ; Wang, JL; Wu, L; Xia, Y; Yang, JD; Yao, LB; Zhang, J; Zhang, ZG1

Reviews

1 review(s) available for astragaloside a and Parkinson Disease

ArticleYear
Astragaloside IV Supplementation Promotes A Neuroprotective Effect in Experimental Models of Neurological Disorders: A Systematic Review.
    Current neuropharmacology, 2019, Volume: 17, Issue:7

    Topics: Alzheimer Disease; Animals; Brain Ischemia; Encephalomyelitis; Humans; Nervous System Diseases; Neuroprotective Agents; Parkinson Disease; Saponins; Triterpenes

2019

Other Studies

4 other study(ies) available for astragaloside a and Parkinson Disease

ArticleYear
Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson's disease treatment.
    Materials science & engineering. C, Materials for biological applications, 2021, Volume: 129

    Topics: Dopaminergic Neurons; Humans; Leptin; Liposomes; Parkinson Disease; Phosphatidylserines; Saponins; tau Proteins; Triterpenes; Wheat Germ Agglutinins

2021
Astragaloside-IV regulates endoplasmic reticulum stress-mediated neuronal apoptosis in a murine model of Parkinson's disease via the lincRNA-p21/CHOP pathway.
    Experimental and molecular pathology, 2020, Volume: 115

    Topics: Animals; Apoptosis; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Endoplasmic Reticulum Stress; Male; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Parkinson Disease; Protein Stability; RNA, Long Noncoding; Saponins; Signal Transduction; Transcription Factor CHOP; Triterpenes

2020
Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
    Neurochemistry international, 2009, Volume: 55, Issue:6

    Topics: Animals; Animals, Newborn; Cell Death; Cell Differentiation; Cells, Cultured; Dopamine; Dose-Response Relationship, Drug; Nerve Degeneration; Neurites; Neurons; Neuroprotective Agents; Nitric Oxide Synthase Type I; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Saponins; Substantia Nigra; Sympatholytics; Triterpenes; Tyrosine 3-Monooxygenase

2009
Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production.
    Molecular and cellular biochemistry, 2012, Volume: 364, Issue:1-2

    Topics: 1-Methyl-4-phenylpyridinium; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Survival; Dopaminergic Neurons; Gene Expression Regulation; Humans; Neuroblastoma; Parkinson Disease; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Saponins; Triterpenes

2012